Diabetic nephropathy, known as diabetic kidney disease (DKD), is a kidney malady frequently found in patients with type 1 and type 2 diabetes. High prevalence of diabetes globally has culminated in diabetes co-morbidities. It can cause nephropathy which would require dialysis or a transplant. The global diabetic nephropathy market report by Market Research Future (MRFR) provides a quantitative and qualitative analysis by listing out trends, factors, and restraints with ample figures and statistics to back up the evidence.
Market Outlook
The global diabetic nephropathy market share is expected to reach a mammoth valuation by exhibiting 5.2% CAGR from 2018 to 2023 (forecast period). This can be attributed to rising cases of obesity and diabetes. Immense demand for diagnostic and imaging tests such as kidney biopsy, blood test, urine test, CT scan, and MRI scans can fuel the market demand. According to the World Health Organization, patients with chronic diseases touched a high of 35 million globally.
Competitive Outlook
Bayer AG, Siemens AG, AbbVie Inc., Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, Reata Pharmaceuticals, Inc., Pfizer Inc., Abbott, Merck Co., Inc., General Electric Company, Novartis AG, Sanofi, and others are some of the noteworthy players in the global diabetic nephropathy market. Increased investments in research and development and drug discovery pertaining to chronic kidney disorders are the main focus of these players.
Segmentation Analysis
The global diabetic nephropathy market is segmented by diagnosis, treatment, indication, and end-user.
By diagnosis, it is segmented into imaging tests, urine tests, blood tests, renal function testing, and kidney biopsy. By treatment, it is segmented into kidney dialysis, medications, and transplant. By indication, it is segmented into diabetes 1 and diabetes 2. By end-user, it is segmented into research institutes, hospitals clinics, diagnostic centers, and others.
Regional Analysis
Europe, the Americas, Asia Pacific (APAC), and the Middle East Africa (MEA) are regions covered in the diabetic nephropathy market report.
The Americas are pegged to lead the global market till 2023 due to emphasis on diagnostic tests, constant monitoring of insulin levels, and large prevalence of chronic kidney disease (CKD). According to the U.S. National Chronic Kidney Disease, nearly 39 million Americans have CKD as of 2019. Large awareness levels can drive the regional market demand. This is exemplified with the American Diabetes Association for creating programs among diabetics for diabetes management.
The European region is deemed to be driven by kidney diagnosis tests for the geriatric populace combined with demand for diagnostic services. Germany is touted to be one of the biggest regions due to investment in new technologies and favorable reimbursement policies. High awareness of diabetes and its negligence which can cause kidney disorders is likely to drive the regional diabetic nephropathy market.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
